Effects of neoadjuvant chemotherapy vs chemoradiotherapy in the treatment of esophageal adenocarcinoma: A systematic review and meta-analysis

Table 1 Characteristic of the studies

Ref.	Design	Center	Country	Year	Number of patients	nCT	nCRT	AC, %
Stahl et al[44], 2017	RCT, Phase III	1	Germany	N/A	119	59	60	100
Burmeister et al[43], 2011	RCT, Phase II	1	Australia	N/A	75	36	39	100
Visser et al[42], 2018	PSM	1	Australia	2000-2017	262	131	131	100
Markar et al[41], 2017	PSM	10	United Kingdom	2001-2012	442	221	221	100
Goense et al[40], 2017	PSM	1	Netherlands	2006-2015	172	86	86	100
Favi et al[39], 2017	PSM	1	Germany	2011-2015	80	40	40	100
Anderegg et al[35], 2017	Cohort, PID	3	Netherlands	2005-2011	313	137	176	100
Spicer et al[38], 2016	Cohort, PID	3	United States	2002-2012	214	114	100	100
Luc et al[36], 2015	Cohort, PID	1	France	2000-2012	116	61	55	100
Münch et al[37], 2018	Cohort, PCCR	70	Germany	1998-2014	135	71	64	100

RCT: Randomized controlled trial; PSM: Propensity score matched cohort; PID: Prospective institutional databases; PCCR: Population-based clinical cancer registry; N/A: Not applicable; nCT: Neoadjuvant chemotherapy; nCRT: Neoadjuvant chemoradiotherapy; AC: Adenocarcinoma.